Detalle Publicación

ARTÍCULO
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Autores: Chari, A. (Autor de correspondencia); Martinez-Lopez, J.; Mateos, M. V.; Blade, J.; Benboubker, L.; Oriol, A.; Arnulf, B.; Rodríguez Otero, Paula; Pineiro, L.; Jakubowiak, A.; de Boer, C.; Wang, J. P.; Clemens, P. L.; Ukropec, J.; Schecter, J.; Lonial, S.; Moreau, P.
Título de la revista: BLOOD
ISSN: 0006-4971
Volumen: 134
Número: 5
Páginas: 421 - 431
Fecha de publicación: 2019
Lugar: WOS
Resumen:
Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy for frontline treatment of multiple myeloma has resulted in a need for effective regimens for lenalidomide-refractory patients. This phase 1b study evaluated daratumumab plus carfilzomib and dexamethasone (D-Kd) in patients with RRMM after 1 to 3 prior lines of therapy, including bortezomib and an immunomodulatory drug; lenalidomiderefractory patients were eligible. Carfilzomib- and daratumumab-naive patients (n 5 85) received carfilzomib weekly on days 1, 8, and 15 of each 28-day cycle (20 mg/m(2) initial dose, escalated to 70 mg/m(2) thereafter) and dexamethasone (40 mg/wk). Of these, 10 patients received the first daratumumab dose as a single infusion (16 mg/kg, day 1 cycle 1), and 75 patients received a split first dose (8 mg/kg, days 1-2 cycle 1). Subsequent dosing was per the approved schedule for daratumumab. Patients received a median of 2 (range, 1-4) prior lines of therapy; 60% were lenalidomide refractory. The most common grade 3/4 treatment-emergent adverse events were thrombocytopenia (31%), lymphopenia (24%), anemia (21%), and neutropenia (21%). Infusion-related reactions were observed in 60% and 43% of single and split first-dose patients, respectively. Overall response rate was 84% (79% in lenalidomide-refractory patients). Median progression-free survival (PFS) was not reached; 12-month PFS rates were 74% for all treated patients and 65% for lenalidomide-refractory patients. D-Kd was well tolerated with low neutropenia rates, and it demonstrated deep responses and encouraging PFS, including in patients refractory to lenalidomide.